<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02555839</url>
  </required_header>
  <id_info>
    <org_study_id>CC-4047-MM-017</org_study_id>
    <nct_id>NCT02555839</nct_id>
  </id_info>
  <brief_title>Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice</brief_title>
  <official_title>Multicenter Non-interventional Study to Investigate Drug Utilization of Pomalidomide in Clinical Practice for the Treatment of Relapsed/Refractory Multiple Myeloma (rrMM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a high unmet medical need for an anti-myeloma therapy for RRMM patients previously
      treated with Lenalidomide and Bortezomib, due to poor prognosis.

      This observational study focuses on the collection of data concerning the safe and optimal
      usage of Pomalidomide, a new therapy option for RRMM patients, thereby increasing the
      knowledge about optimal AE management. Beside this, further analysis of tolerability, dosage
      and efficacy will be performed.

      This knowledge could lead to a optimization of Pomalidomide usage and treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a high unmet medical need for further anti-myeloma therapy in patients with RRMM who
      have previously been treated with Lenalidomide and Bortezomib containing regimens that is
      both active and tolerable, as these patients have a poor prognosis. Hands-on experience with
      Pomalidomide is very limited in Austria and a non-interventional study enhances the attention
      paid to safe use and handling of the product as well as increase knowledge about optimal
      adverse event (AE) management substantially.

      A detailed record of the medical history including. co-morbidities and pre-treatment regimens
      will allow analysis of the impact there of on tolerability, dosage and efficacy.

      Beside the collection of data on efficacy and tolerability this observational drug
      utilization study could give insight into the clinical practice and the routine use of
      Pomalidomide.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2015</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The number of participant adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The number of participants who achieve a response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The number of participants who survive without progression of disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Duration of response is defined as time from the initial documented response (partial response or better) to confirmed disease progression</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Pomalidomide and Dexamethasone</arm_group_label>
    <description>Pomalidomide 4mg capsules by mouth (PO) on days 1 through 21 of a 28 day cycle and Dexamethasone 40mg PO (≤75 years) or 20mg (&gt;75years) on Days 1, 8, 15, 22 of a 28 day cycle until progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pomalidomide, Bortezomib and Dexamethasone</arm_group_label>
    <description>Cycle 1-8: Pomalidomide 4mg capsules by mouth (PO) on days 1 through 14 of a 21 day cycle, Bortezomib (1,3mg/m2) s.c. on day 1, 4, 8, 11 of a 21 day cycle, and Dexamethasone 20mg PO (≤75 years) or 10mg (&gt;75years) on Days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle until progression or unacceptable toxicity; from cycle 9 onwards: Pomalidomide 4mg capsules by mouth (PO) on days 1 through 14 of a 21 day cycle, Bortezomib (1,3mg/m2) s.c. on day 1 and 8 of a 21 day cycle, and Dexamethasone 20mg PO (≤75 years) or 10mg (&gt;75years) on Days 1, 2, 8, 9 of a 21 day cycle until progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>4mg capsule on d1 through 21 of a 28 day cycle</description>
    <arm_group_label>Pomalidomide and Dexamethasone</arm_group_label>
    <other_name>CC-4047</other_name>
    <other_name>Imnovid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40 mg (≤75 years) or 20mg (&gt;75 years) oral on d1, 8, 15, 22 of a 28 day cycle</description>
    <arm_group_label>Pomalidomide and Dexamethasone</arm_group_label>
    <other_name>Fortecortin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>4mg capsule on d1 through 14 of a 21 day cycle</description>
    <arm_group_label>Pomalidomide, Bortezomib and Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>cycle 1-8: 20mg PO (≤75 years) or 10mg (&gt;75years) on Days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle; from cycle 9 onwards: Dexamethasone 20mg PO (≤75 years) or 10mg (&gt;75years) on Days 1, 2, 8, 9 of a 21 day cycle</description>
    <arm_group_label>Pomalidomide, Bortezomib and Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>cycle 1-8: Bortezomib (1,3mg/m2) s.c. on day 1, 4, 8, 11 of a 21 day cycle; from cycle 9 onwards: Bortezomib (1,3mg/m2) s.c. on day 1 and 8 of a 21 day cycle,</description>
    <arm_group_label>Pomalidomide, Bortezomib and Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Relapsed and/or Refractory Multiple Myeloma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed IC

          -  age ≥ 18 years

          -  relapsed/refractory MM

          -  cohort A (combination pomalidomide und dexamethasone):

             ≥2 antimyeloma treatments (including lenalidomide and bortezomib), induction therapy
             followed by ASCT and consolidation or maintenance therapy is considered as 1
             antimyeloma treatment

          -  cohort B (combination pomalidomide, bortezomib and dexamethasone):

             ≥1 antimyeloma treatments (including lenalidomide) induction therapy followed by ASCT
             and consolidation or maintenance therapy is considered as 1 antimyeloma treatment

          -  refractory to last antimyeloma treatment

          -  adequate contraception according to RMP

          -  adequate thrombosis prophylaxis

        Exclusion Criteria:

          1. Pregnant or Lactating Females

          2. Known hypersensitivity to Imnovid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guenter Voraberger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>LKH Feldkirch, Intern E, Hämatologie</name>
      <address>
        <city>Feldkirch</city>
        <zip>6800:</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036:</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KH der Elisabethinen Linz , 1. Interne Hämato-Onkologie</name>
      <address>
        <city>Linz</city>
        <zip>4020:</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kepleruniversitätsklinikum GmbH, Hämatologie und Internistische Onkologie</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Schwestern Ried, Innere Medizin I</name>
      <address>
        <city>Ried</city>
        <zip>4910</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SCRI-CCCIT gemeinnützige GmbH &amp; Universitätsklinikum der PMU Salzburg Gemeinnützige Salzburger Landeskliniken BetriebsgmbH</name>
      <address>
        <city>Salzburg</city>
        <zip>5020:</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LKH Steyr, Innere Medizin II</name>
      <address>
        <city>Steyr</city>
        <zip>4400</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AKH, Innere Medizin I, Klin. Abt. f. Hämatologie</name>
      <address>
        <city>Vienna</city>
        <zip>1090:</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AKH, Universitätsklinik für Innere Medizin I /Klin. Abteilung für Onkologie</name>
      <address>
        <city>Vienna</city>
        <zip>1090:</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Josef Krankenhaus Wien,1. Abteilung für Innere Medizin Zentrum für Onkologie</name>
      <address>
        <city>Vienna</city>
        <zip>1130:</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hanusch Krankenhaus Wien 3. Medizinische Abteilung Hämatolog</name>
      <address>
        <city>Vienna</city>
        <zip>1140:</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital, 1. Med.Abteilung, Zentrum für Onkologie</name>
      <address>
        <city>Vienna</city>
        <zip>1160:</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Salzkammergut-Klinikum Vöcklabruck, Abteilung Innere Medizin</name>
      <address>
        <city>Vöcklabruck</city>
        <zip>4840</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT03723096?term=NCT03723096&amp;rank=1</url>
    <description>Expanded Access for CC-4047</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 18, 2015</study_first_submitted>
  <study_first_submitted_qc>September 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed Multiple Myeloma</keyword>
  <keyword>Refractory Multiple Myeloma</keyword>
  <keyword>Pomalidomide</keyword>
  <keyword>Imnovid</keyword>
  <keyword>Non-interventional</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

